Where Does Acer Therapeutics Inc (ACER) Stock Fall in the Biotechnology Field?

Friday, August 7, 2020 2:41 PM | InvestorsObserver Analysts

Acer Therapeutics Inc (ACER) is around the top of the Biotechnology industry according to InvestorsObserver. ACER received an overall rating of 72, which means that it scores higher than 72 percent of all stocks. Acer Therapeutics Inc also achieved a score of 85 in the Biotechnology industry, putting it above 85 percent of Biotechnology stocks. Biotechnology is ranked 16 out of the 148 industries.

Overall Score - 72
ACER has an Overall Score of 72. Find out what this means to you and get the rest of the rankings on ACER!

What do These Ratings Mean?

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

What's Happening With Acer Therapeutics Inc Stock Today?

Acer Therapeutics Inc (ACER) stock is higher by 20.13% while the S&P 500 is unmoved 0% as of 2:38 PM on Friday, Aug 7. ACER has gained $0.90 from the previous closing price of $4.47 on volume of 2,273,036 shares. Over the past year the S&P 500 has gained 13.99% while ACER has gained 107.34%. ACER lost -$2.62 per share the over the last 12 months.

To see InvestorsObserver's Sentiment Score for Acer Therapeutics Inc click here.

Share this article:

Related Companies

Upgrade to Premium and Analyze Stocks Like a Pro

50% Off All Subscriptions
InvestorsObserver Premium
InvestorsObserver Premium
InvestorsObserver Premium
Save up to 65% with annual

InvestorsObserver Premium

$ 20.75 $ 10.38 /month
$249 $124.50 billed annually

You May Also Like

Related Articles

How Will the Market React to Obseva SA (OBSV) Stock Getting a Bearish Rating

Should You Buy Moderna Inc (MRNA) Stock on Monday?

Is Tenet Healthcare Corp (THC) a Stock to Watch This Week?

European ADRs Move Sharply Higher in Monday Trading

What is the Forecast Price for Puma Biotechnology Inc (PBYI) Stock?

Is The Ensign Group, Inc. (ENSG) Stock Worth a Buy Monday?

Related Companies